Capricor Therapeutics' FDA Decision Delayed by Three Months

What happened

Capricor Therapeutics, a biopharmaceutical company developing treatments for Duchenne muscular dystrophy, announced on August 25, 2026, that the U.S. Food and Drug Administration (FDA) extended the target action date for its Biologics License Application (BLA) for deramiocel. The FDA classified the submission as a major amendment and extended the PDUFA target date by three months, according to a company press release and reports from Investing.com.

Deramiocel is an investigational cell therapy intended to treat Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. The company had previously submitted data to the FDA, and the extension is to allow additional time for review, per the press release.

The stock closed at $9.40 on the event date, up 1.29% from the prior close of $9.28, though other reports noted larger after-hours or pre-market moves following the announcement.

Context and background

The original PDUFA target action date was August 22, 2026. The extension pushes the new date to later in 2026, as reported by Investing.com.

The company's press release, cited in a web search, states that the extension follows discussions with the FDA and that the company plans to submit an amendment including 24-month open-label extension data from the HOPE-3 trial, according to Stocktwits.

Recent reports have raised concerns about the drug's prospects. STAT News published an article on August 20, 2026, suggesting the treatment is heading for an FDA rejection, though the company maintains confidence. Separately, an investor group, Kaos Capital, has called for board changes and a capital-preservation plan, per BioSpace.

The company has no annual revenue as of the latest period ending December 31, 2025, indicating it is a development-stage biotech.

What this means

A PDUFA target action date is the deadline by which the FDA must complete its review of a drug application. The FDA sets these dates under the Prescription Drug User Fee Act, which allows the agency to collect fees from drugmakers to fund faster reviews.

A 'major amendment' is a significant change to an application that the FDA determines requires additional review time. When a company submits new data—here, 24-month follow-up data—the FDA can classify it as a major amendment and extend the target date, typically by three months.

For investors, an extension creates uncertainty about the approval timeline and can pressure a biotech's valuation, as the company waits for a new decision date. The FDA's final decision will determine whether deramiocel can be sold in the U.S. If approved, it would be Capricor's first commercial product; if not, the company faces a longer path.

The stock is trading near $9, reflecting investor caution, but the modest gain on the announcement suggests the market may have partially expected a delay. The next key event is the FDA's decision on the new target date, which will determine the near-term outlook for the company.